Bone and muscle loss after spinal cord injury: Organ interactions

Annals of the New York Academy of Sciences

Volumn 1211, Issue , 2010, Pages 66-84

  Qin, Weiping ^a,b   Bauman, William A ^a,b,c   Cardozo, Christopher ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Department of Medicine ^*  (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Body composition; Bone loss; Estrogen; Insulin like growth factor 1; Methylprednisolone; Muscle atrophy; Spinal cord injury; Testosterone

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN; GLUCOCORTICOID; METHYLPREDNISOLONE; NANDROLONE; OXANDROLONE; PARATHYROID HORMONE; SOMATOMEDIN C; TESTOSTERONE; VITAMIN D;

ARTICLE; BONE CELL; BONE DENSITY; BONE MINERALIZATION; BRAIN DYSFUNCTION; CALCIUM HOMEOSTASIS; CORTICOSTEROID THERAPY; GENE EXPRESSION PROFILING; HUMAN; INSULIN RESISTANCE; MECHANICAL STRESS; MUSCLE ATROPHY; MUSCLE CONTRACTION; MUSCLE MASS; OSTEOLYSIS; SKELETAL MUSCLE; SPINAL CORD INJURY;

EID: 78349252590     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05806.x     Document Type: Article

References (209)

1. Acton, P.A. et al 1993. Traumatic spinal cord injury in Arkansas, 1980 to 1989. Arch. Phys. Med. Rehabil. 74: 1035-1040.
2. Guertin, P.A. 2008. A technological platform to optimize combinatorial treatment design and discovery for chronic spinal cord injury. J. Neurosci. Res. 86: 3039-3051.
3. Berkowitz, M. (ed.) 1998. Spinal Cord Injury-An Analysis of Medical and Social Costs. Vol. 107, Demos Medical Publishing. New York
4. Dudley-Javoroski, S. & R.K. Shields 2008. Muscle and bone plasticity after spinal cord injury: review of adaptations to disuse and to electrical muscle stimulation. J. Rehabil. Res. Dev. 45: 283-296.
5. Biering-Sorensen, B., I.B. Kristensen, M. Kjaer & F. Biering-Sorensen 2009. Muscle after spinal cord injury. Muscle Nerve 40: 499-519.
6. Jiang, S.D., L.Y. Dai & L.S. Jiang 2006. Osteoporosis after spinal cord injury. Osteoporos Int. 17: 180-192.
7. Bauman, W.A., R.H. Adkins, A.M. Spungen & R.L. Waters 1999. The effect of residual neurological deficit on oral glucose tolerance in persons with chronic spinal cord injury. Spinal Cord 37: 765-771.
8. Bauman, W.A. & A.M. Spungen 1994. Disorders of carbohydrate and lipid metabolism in veterans with paraplegia or quadriplegia: a model of premature aging. Metabolism 43: 749-756.
9. Bauman, W.A. et al 1992. Coronary artery disease: metabolic risk factors and latent disease in individuals with paraplegia. Mt. Sinai J. Med. 59: 163-168.
10. Bauman, W.A. et al 1992. Depressed serum high density lipoprotein cholesterol levels in veterans with spinal cord injury. Paraplegia 30: 697-703.
11. Tsitouras, P.D., Y.G. Zhong, A.M. Spungen & W.A. Bauman 1995. Serum testosterone and growth hormone/insulin-like growth factor-I in adults with spinal cord injury. Horm. Metab. Res. 27: 287-292.
12. Adams, M.M. & A.L. Hicks 2005. Spasticity after spinal cord injury. Spinal Cord 43: 577-586.
13. Mathias, C.J. & H.L. Frankel 1988. Cardiovascular control in spinal man. Annu. Rev. Physiol. 50: 77-592.
14. Bickel, C.S., J.M. Slade & G.A. Dudley 2004. Long-term spinal cord injury increases susceptibility to isometric contraction-induced muscle injury. Eur. J. Appl. Physiol. 91: 308-313.
15. Lin, J. et al 2002. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 418: 797-801.
16. Rosen, E.D. & B.M. Spiegelman 2001. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J. Biol. Chem. 276: 37731-37734.
17. Sacheck, J.M. et al 2007. Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases. FASEB J. 21: 140-155.
18. Handschin, C. et al 2007. Skeletal muscle fiber-type switching, exercise intolerance, and myopathy in PGC-1alpha muscle-specific knock-out animals. J. Biol. Chem. 282: 30014-30021.
19. Zeman, R.J. et al 2009. Differential skeletal muscle gene expression after upper or lower motor neuron transection. Pflugers Arch. 458: 525-535.
20. Urso, M.L. et al 2007. Alterations in mRNA expression and protein products following spinal cord injury in humans. J. Physiol. 579: 877-892.
21. Clarke, B.A. et al 2007. The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab. 6: 376-385.
22. Bodine, S.C. et al 2001. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294: 1704-1708.
23. Sandri, M. et al 2006. PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc. Natl. Acad. Sci. USA 103: 16260-16265.
24. Wang, X. et al 2005. Runx1 prevents wasting, myofibrillar disorganization, and autophagy of skeletal muscle. Genes Dev. 19: 1715-1722.
25. Zhao, J. et al 2008. Effects of nandrolone on denervation atrophy depend upon time after nerve transection. Muscle Nerve 37: 42-49.
26. Sabatier, M.J. et al 2006. Electrically stimulated resistance training in SCI individuals increases muscle fatigue resistance but not femoral artery size or blood flow. Spinal Cord 44: 227-233.
27. Baldi, J.C., R.D. Jackson, R. Moraille & W.J. Mysiw 1998. Muscle atrophy is prevented in patients with acute spinal cord injury using functional electrical stimulation. Spinal Cord 36: 463-469.
28. Kim, S.J. et al 2008. Gene expression during inactivity-induced muscle atrophy: effects of brief bouts of a forceful contraction countermeasure. J. Appl. Physiol. 105: 1246-1254.
29. Adams, G.R. 2002. Autocrine and/or paracrine insulin-like growth factor-I activity in skeletal muscle. Clin. Orthop. Relat. Res., 403 Suppl. S188-S196.
30. Lange, S. et al 2005. The kinase domain of titin controls muscle gene expression and protein turnover. Science 308: 1599-1603.
31. Sakamoto, K. & L.J. Goodyear 2002. Invited review: intracellular signaling in contracting skeletal muscle. J. Appl. Physiol. 93: 369-383.
32. Semsarian, C. et al 1999. Skeletal muscle hypertrophy is mediated by a Ca2+-dependent calcineurin signalling pathway. Nature 400: 576-581.
33. Schiaffino, S. & A. Serrano 2002. Calcineurin signaling and neural control of skeletal muscle fiber type and size. Trends Pharmacol. Sci. 23: 569-575.
34. Bassel-Duby, R. & E.N. Olson 2006. Signaling pathways in skeletal muscle remodeling. Annu. Rev. Biochem. 75: 19-37.
35. Dunn, S.E., J.L. Burns & R.N. Michel 1999. Calcineurin is required for skeletal muscle hypertrophy. J. Biol. Chem. 274: 21908-21912.
36. Dunn, S.E., E.R. Chin & R.N. Michel 2000. Matching of calcineurin activity to upstream effectors is critical for skeletal muscle fiber growth. J. Cell Biol. 151: 663-672.
37. Bodine, S.C. et al 2001. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat. Cell Biol. 3: 1014-1019.
38. Dupont-Versteegden, E.E., M. Knox, C.M. Gurley, et al 2002. Maintenance of muscle mass is not dependent on the calcineurin-NFAT pathway. Am. J. Physiol. Cell Physiol. 282: C1387-C1395.
39. Li, H.H. et al 2004. Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. J. Clin. Invest. 114: 1058-1071.
40. Akimoto, T. et al 2005. Exercise stimulates Pgc-1alpha transcription in skeletal muscle through activation of the p38 MAPK pathway. J. Biol. Chem. 280: 19587-19593.
41. Calabria, E. et al 2009. NFAT isoforms control activity-dependent muscle fiber type specification. Proc. Natl. Acad. Sci. USA 106: 13335-13340.
42. Mohr, T. et al 1997. Long-term adaptation to electrically induced cycle training in severe spinal cord injured individuals. Spinal Cord 35: 1-16.
43. Giangregorio, L. & N. McCartney 2006. Bone loss and muscle atrophy in spinal cord injury: epidemiology, fracture prediction, and rehabilitation strategies. J. Spinal Cord Med. 29: 489-500.
44. Szollar, S.M., E.M. Martin, D.J. Sartoris, et al 1998. Bone mineral density and indexes of bone metabolism in spinal cord injury. Am. J. Phys. Med. Rehabil. 77: 28-35.
45. Garland, D.E., R.H. Adkins, V. Kushwaha & C. Stewart 2004. Risk factors for osteoporosis at the knee in the spinal cord injury population. J. Spinal Cord Med. 27: 202-206.
46. Warden, S.J. et al 2002. Quantitative ultrasound assessment of acute bone loss following spinal cord injury: a longitudinal pilot study. Osteoporos. Int. 13: 586-592.
47. Vico, L. et al 2000. Effects of long-term microgravity exposure on cancellous and cortical weight-bearing bones of cosmonauts. Lancet 355: 1607-1611.
48. Leblanc, A.D., V.S. Schneider, H.J. Evans, et al 1990. Bone mineral loss and recovery after 17 weeks of bed rest. J. Bone Miner. Res. 5: 843-850.
49. Berarducci, A. 2009. Stopping the silent progression of osteoporosis. Am. Nurse Today 3: 18.
50. Eser, P. et al 2004. Relationship between the duration of paralysis and bone structure: a pQCT study of spinal cord injured individuals. Bone 34: 869-880.
51. Bauman, W.A., A.M. Spungen, J. Wang, et al 1999. Continuous loss of bone during chronic immobilization: a monozygotic twin study. Osteoporos. Int. 10: 123-127.
52. De Bruin, E.D., V. Dietz, M.A. Dambacher & E. Stussi 2000. Longitudinal changes in bone in men with spinal cord injury. Clin. Rehabil. 14: 145-152.
53. Dauty, M., B. Perrouin Verbe, Y. Maugars, et al 2000. Supralesional and sublesional bone mineral density in spinal cord-injured patients. Bone 27: 305-309.
54. Biering-Sorensen, F., H.H. Bohr & O.P. Schaadt 1990. Longitudinal study of bone mineral content in the lumbar spine, the forearm and the lower extremities after spinal cord injury. Eur. J. Clin. Invest. 20: 330-335.
55. Finsen, V., B. Indredavik & K.J. Fougner 1992. Bone mineral and hormone status in paraplegics. Paraplegia 30: 343-347.
56. Frey-Rindova, P., E.D. De Bruin, E. Stussi, et al 2000. Bone mineral density in upper and lower extremities during 12 months after spinal cord injury measured by peripheral quantitative computed tomography. Spinal Cord 38: 26-32.
57. Eser, P., A. Frotzler, Y. Zehnder & J. Denoth 2005. Fracture threshold in the femur and tibia of people with spinal cord injury as determined by peripheral quantitative computed tomography. Arch. Phys. Med. Rehabil. 86: 498-504.
58. Zehnder, Y. et al 2004. Long-term changes in bone metabolism, bone mineral density, quantitative ultrasound parameters, and fracture incidence after spinal cord injury: a cross-sectional observational study in 100 paraplegic men. Osteoporos. Int. 15: 180-189.
59. Morse, L.R. et al 2009. Osteoporotic fractures and hospitalization risk in chronic spinal cord injury. Osteoporos. Int. 20: 385-392.
60. Zeman, R.J., A. Hirschman M.L. Hirschman 1991. Clenbuterol, a beta 2-receptor agonist, reduces net bone loss in denervated hindlimbs. Am. J. Physiol. 261: E285-E289.
61. Bauman, W.A., A.M. Spungen, J. Wang, et al 2006. Relationship of fat mass and serum estradiol with lower extremity bone in persons with chronic spinal cord injury. Am. J. Physiol. Endocrinol. Metab. 290: E1098-E1103.
62. Shields, R.K. & S. Dudley-Javoroski 2006. Musculoskeletal plasticity after acute spinal cord injury: effects of long-term neuromuscular electrical stimulation training. J. Neurophysiol. 95: 2380-2390.
63. Shields, R.K., S. Dudley-Javoroski & L.A. Law 2006. Electrically induced muscle contractions influence bone density decline after spinal cord injury. Spine (Phila Pa 1976) 31: 548-553.
64. Dudley-Javoroski, S. & R.K. Shields 2008. Asymmetric bone adaptations to soleus mechanical loading after spinal cord injury. J. Musculoskelet. Neuronal Interact 8: 227-238.
65. Shields, R.K. & S. Dudley-Javoroski 2007. Musculoskeletal adaptations in chronic spinal cord injury: effects of long-term soleus electrical stimulation training. Neurorehabil. Neural Repair 21: 169-179.
66. Mohr, T. et al 1997. Increased bone mineral density after prolonged electrically induced cycle training of paralyzed limbs in spinal cord injured man. Calcif. Tissue Int. 61: 22-25.
67. Goktepe, A.S., I. Tugcu, B. Yilmaz, et al 2008. Does standing protect bone density in patients with chronic spinal cord injury? J. Spinal Cord Med. 31: 197-201.
68. Giangregorio, L.M. et al 2005. Body weight supported treadmill training in acute spinal cord injury: impact on muscle and bone. Spinal Cord 43: 649-657.
69. Alekna, V., M. Tamulaitiene, T. Sinevicius & A. Juocevicius 2008. Effect of weight-bearing activities on bone mineral density in spinal cord injured patients during the period of the first two years. Spinal Cord 46: 727-732.
70. Lofvenmark, I., L. Werhagen & C. Norrbrink 2009. Spasticity and bone density after a spinal cord injury. J. Rehabil. Med. 41: 1080-1084.
71. Eser, P., A. Frotzler, Y. Zehnder, et al 2005. Assessment of anthropometric, systemic, and lifestyle factors influencing bone status in the legs of spinal cord injured individuals. Osteoporos. Int. 16: 26-34.
72. Gorgey, A.S. & G.A. Dudley 2008. Spasticity may defend skeletal muscle size and composition after incomplete spinal cord injury. Spinal Cord 46: 96-102.
73. Zaidi, M. 2007. Skeletal remodeling in health and disease. Nat. Med. 13: 791-801.
74. Pavalko, F.M. et al 2003. A model for mechanotransduction in bone cells: the load-bearing mechanosomes. J. Cell Biochem. 88: 104-112.
75. Han, Y., S.C. Cowin, M.B. Schaffler & S. Weinbaum 2004. Mechanotransduction and strain amplification in osteocyte cell processes. Proc. Natl. Acad. Sci. USA 101: 16689-16694.
76. Jiang, S.D., L.S. Jiang & L.Y. Dai 2006. Mechanisms of osteoporosis in spinal cord injury. Clin. Endocrinol. (Oxf) 65: 555-565.
77. Bonewald, L.F. & M.L. Johnson 2008. Osteocytes, mechanosensing and Wnt signaling. Bone 42: 606-615.
78. McBeath, R., D.M. Pirone, C.M. Nelson, et al 2004. Cell shape, cytoskeletal tension, and RhoA regulate stem cell lineage commitment. Dev. Cell 6: 483-495.
79. Bergmann, P., A. Heilporn, A. Schoutens 1977. Longitudinal study of calcium and bone metabolism in paraplegic patients. Paraplegia 15: 147-159.
80. Roberts, D. et al Longitudinal study of 1998. bone turnover after acute spinal cord injury. J. Clin. Endocrinol. Metab. 83: 415-422.
81. Pietschmann, P. et al 1992. Increased serum osteocalcin levels in patients with paraplegia. Paraplegia 30: 204-209.
82. Uebelhart, D. et al 1994. Early modifications of biochemical markers of bone metabolism in spinal cord injury patients. A preliminary study. Scand. J. Rehabil. Med. 26: 197-202.
83. Reiter, A.L., A. Volk, J. Vollmar, et al 2007. Changes of basic bone turnover parameters in short-term and long-term patients with spinal cord injury. Eur. Spine J. 16: 771-776.
84. Morse, L.R. et al 2008. Age and motor score predict osteoprotegerin level in chronic spinal cord injury. J. Musculoskelet Neuronal Interact 8: 50-57.
85. Demulder, A. et al 1998. Increased osteoclast-like cells formation in long-term bone marrow cultures from patients with a spinal cord injury. Calcif. Tissue Int. 63: 396-400.
86. Sugawara, H., T.A. Linsenmeyer, H. Beam, & J.R. Parsons 1998. Mechanical properties of bone in a paraplegic rat model. J. Spinal Cord Med. 21: 302-308.
87. Morse, L. et al 2008. Spinal cord injury causes rapid osteoclastic resorption and growth plate abnormalities in growing rats (SCI-induced bone loss in growing rats). Osteoporos Int. 19: 645-652.
88. Jiang, S.D., L.S. Jiang & L.Y. Dai 2007. Effects of spinal cord injury on osteoblastogenesis, osteoclastogenesis and gene expression profiling in osteoblasts in young rats. Osteoporos Int. 18, 339-349.
89. Jiang, S.D., L.S. Jiang & L.Y. Dai 2007. Changes in bone mass, bone structure, bone biomechanical properties, and bone metabolism after spinal cord injury: a 6-month longitudinal study in growing rats. Calcif. Tissue Int. 80: 167-175.
90. Picard, S., N.P. Lapointe, J.P. Brown & P.A. Guertin 2008. Histomorphometric and densitometric changes in the femora of spinal cord transected mice. Anat. Rec. (Hoboken) 291: 303-307.
91. Bracken, M.B. & T.R. Holford 2002. Neurological and functional status 1 year after acute spinal cord injury: estimates of functional recovery in National Acute Spinal Cord Injury Study II from results modeled in National Acute Spinal Cord Injury Study III. J. Neurosurg. 96: 259-266.
92. Bracken, M.B. et al 1998. Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury: 1-year follow up. Results of the third National Acute Spinal Cord Injury randomized controlled trial. J. Neurosurg. 89: 699-706.
93. Bracken, M.B. et al 1997. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 277: 1597-1604.
94. Young, W. & M.B. Bracken 1992. The Second National Acute Spinal Cord Injury Study. J. Neurotrauma 9(Suppl 1): S397-405.
95. Bracken, M.B. et al 1992. Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data. Results of the second National Acute Spinal Cord Injury Study. J. Neurosurg. 76: 23-31.
96. Bracken, M.B. 1991. Treatment of acute spinal cord injury with methylprednisolone: results of a multicenter, randomized clinical trial. J. Neurotrauma 8(Suppl 1): S47-50; discussion S51-S52.
97. Bracken, M.B. et al 1990. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N. Engl. J. Med. 322: 1405-1411.
98. Qian, T. et al 2005. High-dose methylprednisolone may cause myopathy in acute spinal cord injury patients. Spinal Cord 43: 199-203.
99. Nicholas, J.J., D.H. Streeten & L. Jivoff 1969. A study of pituitary and adrenal function in patients with traumatic injuries of the spinal cord. J. Chronic. Dis. 22: 463-471.
100. Zeitzer, J.M., N.T. Ayas, S.A. Shea, et al 2000. Absence of detectable melatonin and preservation of cortisol and thyrotropin rhythms in tetraplegia. J. Clin. Endocrinol. Metab. 85: 2189-2196.
101. Dalla Libera, L. et al 2001. Beneficial effects on skeletal muscle of the angiotensin II type 1 receptor blocker irbesartan in experimental heart failure. Circulation 103: 2195-2200.
102. Brink, M. et al 2001. Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I. Endocrinology. 142: 1489-1496.
103. Wecht, J.M. et al 2009. Orthostatic responses to nitric oxide synthase inhibition in persons with tetraplegia. Arch. Phys. Med. Rehabil. 90: 1428-1434.
104. Bhasin, S. et al 2001. Testosterone dose-response relationships in healthy young men. Am. J. Physiol. Endocrinol. Metab. 281: E1172-E1181.
105. Bhasin, S. et al 2005. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J. Clin. Endocrinol. Metab. 90: 678-688.
106. Mauras, N. et al 1998. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J. Clin. Endocrinol. Metab. 83: 1886-1892.
107. Kostovski, E., P.O. Iversen, K. Birkeland, et al 2008. Decreased levels of testosterone and gonadotrophins in men with long-standing tetraplegia. Spinal Cord. 46: 559-564.
108. Strawford, A. et al 1999. Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss: a randomized controlled trial. JAMA. 281: 1282-1290.
109. Earthman, C.P., P.M. Reid, I.T. Harper, et al 2002. Body cell mass repletion and improved quality of life in HIV-infected individuals receiving oxandrolone. JPEN J. Parenter. Enteral. Nutr. 26: 357-365.
110. Montano, M. et al 2007. Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J. Clin. Endocrinol. Metab. 92: 2793-2802.
111. Schols, A.M., P.B. Soeters, R. Mostert, et al 1995. Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial. Am. J. Respir. Crit. Care Med. 152: 1268-1274.
112. Yeh, S.S., B. DeGuzman & T. Kramer 2002. Reversal of COPD-associated weight loss using the anabolic agent oxandrolone. Chest. 122: 421-428.
113. Demling, R.H. & L. DeSanti 1997. Oxandrolone, an anabolic steroid, significantly increases the rate of weight gain in the recovery phase after major burns. J. Trauma 43: 47-51.
114. Wolf, S.E. et al 2006. Effects of oxandrolone on outcome measures in the severely burned: a multicenter prospective randomized double-blind trial. J. Burn Care Res. 27: 131-139. discussion 140-131.
115. Crawford, B.A., P.Y. Liu, M.T. Kean, et al 2003. Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J. Clin. Endocrinol. Metab. 88: 3167-3176.
116. Wimalawansa, S.M. et al 1999. Reversal of weightlessness-induced musculoskeletal losses with androgens: quantification by MRI. J. Appl. Physiol. 86: 1841-1846.
117. Taylor, D.C., D.E. Brooks & J.B. Ryan 1999. Anabolic-androgenic steroid administration causes hypertrophy of immobilized and nonimmobilized skeletal muscle in a sedentary rabbit model. Am. J. Sports Med. 27: 718-727.
118. Zhao, W. et al 2008. Testosterone protects against dexamethasone-induced muscle atrophy, protein degradation and MAFbx upregulation. J. Steroid Biochem. Mol. Biol. 110: 125-129.
119. Gregory, C.M., K. Vandenborne, H.F. Huang, et al 2003. Effects of testosterone replacement therapy on skeletal muscle after spinal cord injury. Spinal Cord. 41: 23-28.
120. Sheffield-Moore, M. et al 1999. Short-term oxandrolone administration stimulates net muscle protein synthesis in young men. J. Clin. Endocrinol. Metab. 84: 2705-2711.
121. Sarbassov, D.D., S.M. Ali & D.M. Sabatini 2005. Growing roles for the mTOR pathway. Curr. Opin. ell Biol. 17: 596-603.
122. Xu, T. et al 2004. Phosphorylation of p70s6 kinase is implicated in androgen-induced levator ani muscle anabolism in castrated rats. J. Steroid Biochem. Mol. Biol. 92: 447-454.
123. Rommel, C. et al 2001. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol. 3: 1009-1013.
124. Schakman, O. et al 2005. Insulin-like growth factor-I gene transfer by electroporation prevents skeletal muscle atrophy in glucocorticoid-treated rats. Endocrinology 146: 1789-1797.
125. Dehoux, M. et al 2004. Role of the insulin-like growth factor I decline in the induction of atrogin-1/MAFbx during fasting and diabetes. Endocrinology 145: 4806-4812.
126. Alzghoul, M.B., D. Gerrard, B.A. Watkins & K. Hannon 2004. Ectopic expression of IGF-I and Shh by skeletal muscle inhibits disuse-mediated skeletal muscle atrophy and bone osteopenia in vivo. FASEB J. 18: 221-223.
127. Wu, Y. et al 2007. Identification of Androgen Response Elements in the IGF-1 Upstream Promoter. Endocrinology 148: 2984-2993.
128. Ferrando, A.A. et al 2002. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am. J. Physiol. Endocrinol. Metab. 282: E601-607.
129. Sofer, A., K. Lei, C.M. Johannessen, & L.W. Ellisen, 2005. Regulation of mTOR and cell growth in response to energy stress by REDD1. Mol. Cell Biol. 25: 5834-5845.
130. Wang, H., N. Kubica, L.W. Ellisen, L.S. Jefferson, & S.R. Kimball 2006. Dexamethasone represses signaling through the mammalian target of rapamycin in muscle cells by enhancing expression of REDD1. J. Biol. Chem. 281: 39128-39134.
131. Wu, Y. et al 2009. REDD1 Is a Major Target of Testosterone Action in Preventing Dexamethasone-Induced Muscle Loss. Endocrinology.
132. Ferrando, A.A., M. Sheffield-Moore, S.E. Wolf, et al 2001. Testosterone administration in severe burns ameliorates muscle catabolism. Crit. Care Med. 29: 1936-1942.
133. Sandri, M. et al 2004. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117: 399-412.
134. Stitt, T.N. et al 2004. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol. Cell 14: 395-403.
135. Bauman, W.A. et al 2006. Effect of low-dose baclofen administration on plasma insulin-like growth factor-I in persons with spinal cord injury. J. Clin. Pharmacol. 46: 476-482.
136. Hawley, J.A. 2004. Exercise as a therapeutic intervention for the prevention and treatment of insulin resistance. Diabetes Metab. Res. Rev. 20: 383-393.
137. Frosig, C. & E.A. Richter 2009. Improved insulin sensitivity after exercise: focus on insulin signaling. Obesity (Silver Spring) 17(Suppl 3): S15-S20.
138. Mohr, T. et al 2001. Insulin action and long-term electrically induced training in individuals with spinal cord injuries. Med. Sci. Sports Exerc. 33: 1247-1252.
139. Spungen, A.M., J. Wang, R.N. Pierson, et al 2000. Soft tissue body composition differences in monozygotic twins discordant for spinal cord injury. J. Appl. Physiol. 88: 1310-1315.
140. Spungen, A.M. et al 2003. Factors influencing body composition in persons with spinal cord injury: a cross-sectional study. J. Appl. Physiol. 95: 2398-2407.
141. Elder, C.P., D.F. Apple, C.S. Bickel, et al 2004. Intramuscular fat and glucose tolerance after spinal cord injury-a cross-sectional study. Spinal Cord 42: 711-716.
142. Gorgey, A.S. & G.A. Dudley 2007. Skeletal muscle atrophy and increased intramuscular fat after incomplete spinal cord injury. Spinal Cord 45: 304-309.
143. Goodpaster, B.H., F.L. Thaete, J.A. Simoneau & D.E. Kelley 1997. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 46: 1579-1585.
144. Goodpaster, B.H., J. He, S. Watkins & D.E. Kelley 2001. Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes. J. Clin. Endocrinol. Metab. 86: 5755-5761.
145. Hafer-Macko, C.E., S. Yu, A.S. Ryan, et al 2005. Elevated tumor necrosis factor-alpha in skeletal muscle after stroke. Stroke 36: 2021-2023.
146. Szulc, P. et al 2001. Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS study. J. Clin. Endocrinol. Metab. 86: 192-199.
147. Khosla, S., L.J. Melton, 3rd, E.J. Atkinson & W.M. O'Fallon 2001. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J. Clin. Endocrinol. Metab. 86: 3555-3561.
148. Riggs, B.L., S. Khosla & L.J. Melton, 3rd. 1998. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J. Bone Miner. Res. 13: 763-773.
149. Khosla, S., L.J. Melton, 3rd & B.L. Riggs 2002. Clinical review 144: Estrogen and the male skeleton. J. Clin. Endocrinol. Metab. 87: 1443-1450.
150. Gennari, L., S. Khosla & J.P. Bilezikian 2008. Estrogen and fracture risk in men. J. Bone. Miner. Res. 23: 1548-1551.
151. Vandenput, L. & C. Ohlsson 2009. Estrogens as regulators of bone health in men. Nat. Rev. Endocrinol. 5: 437-443.
152. Kley, H.K., T. Deselaers, H. Peerenboom & H.L. Kruskemper 1980. Enhanced conversion of androstenedione to estrogens in obese males. J. Clin. Endocrinol. Metab. 51: 1128-1132.
153. Simpson, E.R. 2000. Role of aromatase in sex steroid action. J. Mol. Endocrinol. 25: 149-156.
154. Napoli, N. et al 2007. Estrogen metabolism modulates bone density in men. Calcif. Tissue Int. 80: 227-232.
155. LeBlanc, E.S. et al 2009. The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men. J. Clin. Endocrinol. Metab. 94: 3337-3346.
156. Gu, G., T.A. Hentunen, M. Nars, et al 2005. Estrogen protects primary osteocytes against glucocorticoid-induced apoptosis. Apoptosis 10: 583-595.
157. Huang, Q.Y., G.H. Li & A.W. Kung 2009. The -9247 T/C polymorphism in the SOST upstream regulatory region that potentially affects C/EBPalpha and FOXA1 binding is associated with osteoporosis. Bone 45: 289-294.
158. Notelovitz, M. 2002. Androgen effects on bone and muscle. Fertil Steril 77(Suppl 4), S34-S41.
159. Francis, R.M.N. 1999. The effects of testosterone on osteoporosis in men. Clin. Endocrinol. (Oxf) 50: 411-414.
160. Anderson, F.H., R.M. Francis, P.L. Selby & C. Cooper 1998. Sex hormones and osteoporosis in men. Calcif. Tissue Int. 62: 185-188.
161. Pederson, L. et al 1999. Androgens regulate bone resorption activity of isolated osteoclasts in vitro. Proc. Natl. Acad. Sci. USA 96: 505-510.
162. Cardozo, C.P. et al 2010. Nandrolone slows hindlimb bone loss in a rat model of bone loss due to denervation. Ann. N. Y. Acad. Sci. 1192: 303-306.
163. Bauman, W.A. & A.M. Spungen 2000. Metabolic changes in persons after spinal cord injury. Phys. Med. Rehabil. Clin. N. Am. 11: 109-140.
164. Claus-Walker, J., R.J. Campos, R.E. Carter, et al 1972. Calcium excretion in quadriplegia. Arch. Phys. Med. Rehabil. 53: 14-20.
165. Maynard, F.M. 1986. Immobilization hypercalcemia following spinal cord injury. Arch. Phys. Med. Rehabil. 67: 41-44.
166. Naftchi, N.E., A.T. Viau, G.H. Sell & E.W. Lowman 1980. Mineral metabolism in spinal cord injury. Arch. Phys. Med. Rehabil. 61: 139-142.
167. Tori, J.A. & L.L. Hil 1978. Hypercalcemia in children with spinal cord injury. Arch. Phys. Med. Rehabil. 59: 443-446.
168. Kaplan, P.E., B. Gandhavadi, L. Richards & J. Goldschmidt 1978. Calcium balance in paraplegic patients: influence of injury duration and ambulation. Arch. Phys. Med. Rehabil. 59: 447-450.
169. Stewart, A.F., M. Adler, C.M. Byers, et al 1982. Calcium homeostasis in immobilization: an example of resorptive hypercalciuria. N. Engl. J. Med. 306: 1136-1140.
170. Mechanick, J.I. et al 1997. Parathyroid hormone suppression in spinal cord injury patients is associated with the degree of neurologic impairment and not the level of injury. Arch. Phys. Med. Rehabil. 78: 692-696.
171. Loomis, W.F. 1967. Skin-pigment regulation of vitamin-D biosynthesis in man. Science 157: 501-506.
172. Comarr, A.E., R.H. Hutchinson & E. Bors 1962. Extremity fractures of patients with spinal cord injuries. Am. J. Surg. 103: 732-739.
173. Hahn, T.J., B.A. Hendin, C.R. Scharp & J.G. Haddad Jr. 1972. Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults. N. Engl. J. Med. 287: 900-904.
174. Bauman, W.A., Y.G. Zhong & E. Schwartz 1995. Vitamin D deficiency in veterans with chronic spinal cord injury. Metabolism 44: 1612-1616.
175. Miao, D. et al 2004. Skeletal abnormalities in Pth-null mice are influenced by dietary calcium. Endocrinology 145: 2046-2053.
176. Lips, P., W.H. Hackeng, M.J. Jongen, et al 1983. Seasonal variation in serum concentrations of parathyroid hormone in elderly people. J. Clin. Endocrinol. Metab. 57: 204-206.
177. Chapuy, M.C. et al 1983. Healthy elderly French women living at home have secondary hyperparathyroidism and high bone turnover in winter. EPIDOS Study Group. J. Clin. Endocrinol. Metab. 81: 1129-1133.
178. Bauman, W.A., R.L. Zhang, N. Morrison & A.M. Spungen 2009. Acute suppression of bone turnover with calcium infusion in persons with spinal cord injury. J. Spinal Cord Med. 32: 398-403.
179. Scelsi, R. et al 1986. Skeletal muscle changes following myelotomy in paraplegic patients. Paraplegia 24: 250-259.
180. Edgerton, V.R. et al 2008. Training locomotor networks. Brain Res. Rev. 57: 241-254.
181. Hyatt, J.P., R.R. Roy, K.M. Baldwin & V.R. Edgerton 2003. Nerve activity-independent regulation of skeletal muscle atrophy: role of MyoD and myogenin in satellite cells and myonuclei. Am. J. Physiol. Cell Physiol. 285: C1161-C1173.
182. Hyatt, J.P., R.R. Roy, K.M. Baldwin, et al 2006. Activity-unrelated neural control of myogenic factors in a slow muscle. Muscle Nerve 33: 49-60.
183. Takeda, S. et al 2002. Leptin regulates bone formation via the sympathetic nervous system. Cell 111: 305-317.
184. Sato, S. et al 2007. Central control of bone remodeling by neuromedin U. Nat. Med. 13: 1234-1240.
185. Bjurholm, A., A. Kreicbergs, E. Brodin & M. Schultzberg 1988. Substance P- and CGRP-immunoreactive nerves in bone. Peptides 9: 165-171.
186. Hukkanen, M. et al 1992. Innervation of bone from healthy and arthritic rats by substance P and calcitonin gene related peptide containing sensory fibers. J. Rheumatol. 19: 1252-1259.
187. Juarranz, Y. et al 2005. Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res. Ther. 7: R1034-R1045.
188. Mukohyama, H., M. Ransjo, H. Taniguchi, et al 2000. The inhibitory effects of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on osteoclast formation are associated with upregulation of osteoprotegerin and downregulation of RANKL and RANK. Biochem. Biophys. Res. Commun. 271: 158-163.
189. Fu, L., M. S. Patel, A. Bradley, et al 2005. The molecular clock mediates leptin-regulated bone formation. Cell 122: 803-815.
190. Olive, J.L., G.A. Dudley & K.K. McCully 2003. Vascular remodeling after spinal cord injury. Med. Sci. Sports Exerc. 35: 901-907.
191. Castro, M.J., D.F. Apple Jr., S. Rogers & G.A. Dudley 2000. Influence of complete spinal cord injury on skeletal muscle mechanics within the first 6 months of injury. Eur. J. Appl. Physiol. 81: 128-131.
192. Wilmet, E., A.A. Ismail, A. Heilporn, et al 1995. Longitudinal study of the bone mineral content and of soft tissue composition after spinal cord section. Paraplegia 33: 674-677.
193. McDonald, C.M., A.L. Abresch-Meyer, M.D. Nelson & L.M. Widman 2007. Body mass index and body composition measures by dual x-ray absorptiometry in patients aged 10 to 21 years with spinal cord injury. J. Spinal Cord Med. 30(Suppl 1): S97-S104.
194. Trudel, G. et al. 2009. Bone marrow fat accumulation after 60 days of bed rest persisted 1 year after activities were resumed along with hemopoietic stimulation: the Women International Space Simulation for Exploration study. J. Appl. Physiol. 107: 540-548.
195. Minaire, P., C. Edouard, M. Arlot & P.J. Meunier 1984. Marrow changes in paraplegic patients. Calcif. Tissue Int. 36: 338-340.
196. Jee, W.S., T.J. Wronski, E.R. Morey & D.B. Kimmel 1983. Effects of spaceflight on trabecular bone in rats. Am. J. Physiol. 244: R310-R314.
197. Wronski, T.J. & E.R. Morey 1982. Skeletal abnormalities in rats induced by simulated weightlessness. Metab. Bone Dis. Relat. Res. 4: 69-75.
198. Schopp, L.H. et al 2006. Testosterone levels among men with spinal cord injury admitted to inpatient rehabilitation. Am. J. Phys. Med. Rehabil. 85: 678-684; quiz 685-677.
199. Singh, R. et al 2006. Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology 147: 141-154.
200. Menagh, P. et al 2009. Growth hormone regulates the balance between bone formation and bone marrow adiposity. J. Bone Miner. Res.
201. Johnson, T.E., R. Vogel, S. J. Rutledge, et al 1999. Thiazolidinedione effects on glucocorticoid receptor-mediated gene transcription and differentiation in osteoblastic cells. Endocrinology 140: 3245-3254.
202. Ishida, Y. & J.N. Heersche 1998. Glucocorticoid-induced osteoporosis: both in vivo and in vitro concentrations of glucocorticoids higher than physiological levels attenuate osteoblast differentiation. J. Bone Miner. Res. 13: 1822-1826.
203. David, V. et al 2007. Mechanical loading down-regulates peroxisome proliferator-activated receptor gamma in bone marrow stromal cells and favors osteoblastogenesis at the expense of adipogenesis. Endocrinology 148: 2553-2562.
204. Zalavras, C., S. Shah, M.J. Birnbaum & B. Frenkel 2003. Role of apoptosis in glucocorticoid-induced osteoporosis and osteonecrosis. Crit. Rev. Eukaryot. Gene Expr. 13: 221-235.
205. Karastergiou, K. & V. Mohamed-Ali The autocrine and paracrine roles of adipokines. Mol. Cell Endocrinol. 318: 69-78.
206. Dyck, D.J. 2009. Adipokines as regulators of muscle metabolism and insulin sensitivity. Appl. Physiol. Nutr. Metab. 34: 396-402.
207. Lago, F., R. Gomez, J.J. Gomez-Reino, C. Dieguez & O. Gualillo 2009. Adipokines as novel modulators of lipid metabolism. Trends Biochem. Sci. 34: 500-510.
208. Bauman, W.A., A.M. Spungen, Y.G. Zhong & C.V. Mobbs 1996. Plasma leptin is directly related to body adiposity in subjects with spinal cord injury. Horm. Metab. Res. 28: 732-736.
209. Maruyama, Y. et al 2008. Serum leptin, abdominal obesity and the metabolic syndrome in individuals with chronic spinal cord injury. Spinal Cord 46: 494-499.